相关实验视频

Updated: Jun 13, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

在宫癌中识别化疗-放射治疗敏感性的枢纽基因:在分析中的双数据集

Yanhong Wang¹, Yi Ouyang², Xinping Cao²

¹Department of Radiotherapy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian, China.

Discover oncology

|September 12, 2024

概括

包括SELP和PIM2在内的6个枢纽基因与宫癌 (CESC) 中的化疗放射治疗敏感性有关. 这些基因可以预测治疗反应和患者的预后,为改善结果提供潜在的生物标志物.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
生物标志物生物标志物

背景情况:

宫癌 (CESC) 是一个重大的全球健康挑战.
确定可靠的化学放射治疗敏感性的生物标志物对于有效的治疗策略至关重要.

研究的目的:

确定关键基因 (枢纽基因) 与宫癌中化疗放射治疗敏感性相关.
探索这些枢纽基因在CESC进展中的功能作用和调控机制.

主要方法:

利用了来自GEO和TCGA数据库的基因表达数据,用于CESC患者.
采用基因本体学 (GO) 和KEGG通路分析来进行功能丰富.
通过随机生存森林分析识别了中心基因,并通过人类蛋白质图谱 (HPA) 验证了表达.

主要成果:

在CESC中确定了139个上调和13个下调的差异表达基因 (DEG).
六个枢纽基因 (SELP,PIM2,CCL19,SDS,NRP1,SF3A2) 与免疫透,化疗敏感性和丰富的通路显著相关 (p <0.05).
开发了一种具有高准确度的预测性预后表,并构建了监管和ceRNA网络.

结论:

已识别的枢纽基因 (SELP,PIM2,CCL19,SDS,NRP1,SF3A2) 与CESC中的放射治疗敏感性有关.
这些基因与各种细胞过程有关,可以作为宫癌患者放射治疗反应和预后的预测生物标志物.

关键词:

宫癌是发生在宫癌的原因之一.化学辐射疗法敏感性化学辐射疗法敏感性枢纽基因枢纽基因枢纽基因这个名字叫做Nomogram.信号通道的信号通道.

更多相关视频

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...